QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
LON:IXI

IXICO (IXI) Share Forecast, Price & News

GBX 19.40
0.00 (0.00%)
(As of 09/21/2023 ET)
Compare
Today's Range
18.72
19.40
50-Day Range
18.44
21
52-Week Range
16.34
38.84
Volume
652 shs
Average Volume
32,458 shs
Market Capitalization
£9.38 million
P/E Ratio
975.00
Dividend Yield
N/A
Price Target
N/A

IXI stock logo

About IXICO (LON:IXI) Stock

IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. In addition, the company focuses in therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other diseases, Progressive Supranuclear Palsy, and other rare neurological diseases. Further, the company engages in the data collection and analysis of neurological disorders; offers drug development analytics, imaging operation services, and post marketing surveillance services, as well as consultancy services; and provides end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.

IXI Price History

IXI Stock News Headlines

Overlooked AI Stock Gets Urgent "Buy"
We issued our first "Buy" rating on Apple when it traded at the equivalent of 56 cents per share. It's up 32,571% since. And while Nvidia is up 3x this year… We called it back in 2011. And it has surged 97x (9,624% to be exact) since then. Now, our Weiss Ratings has issued a "Buy" on a stock that's leading the AI revolution in one of the most profitable industries.
IXICO 'on track' to achieve full-year guidance
Overlooked AI Stock Gets Urgent "Buy"
We issued our first "Buy" rating on Apple when it traded at the equivalent of 56 cents per share. It's up 32,571% since. And while Nvidia is up 3x this year… We called it back in 2011. And it has surged 97x (9,624% to be exact) since then. Now, our Weiss Ratings has issued a "Buy" on a stock that's leading the AI revolution in one of the most profitable industries.
IXICO upbeat on prospects as it eyes double-digit growth
IXICO upbeat on prospects as eyes double-digit growth
Clinical Trials Imaging Market Outlook By 2031
FTSE 100 slumps to two-month lows - Market Report
Ixico Wins Services Contract for Dementia Study
See More Headlines
Receive IXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IXICO and its competitors with MarketBeat's FREE daily newsletter.

IXI Company Calendar

Last Earnings
5/20/2020
Today
9/21/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
90
Year Founded
N/A

Profitability

Net Income
£1.03 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£7.92 million
Cash Flow
GBX 8.62 per share
Book Value
GBX 25 per share

Miscellaneous

Free Float
N/A
Market Cap
£9.38 million
Optionable
Not Optionable
Beta
0.61
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Giulio Cerroni (Age 61)
    CEO & Director
    Comp: $317.5k
  • Mr. Grant Nash
    CFO, Company Sec. & Exec. Director
  • Prof. Daniel Rueckert
    Co-Founder & Member of Scientific Advisory Board
  • Prof. Derek Lionel Glendon Hill (Age 57)
    Co-Founder and Pres of Regulatory Science & External Relations
  • Prof. David Hawkes
    Co-Founder & Member of Scientific Advisory Board
  • Prof. Joseph Hajnal
    Co-Founder & Member of Scientific Advisory Board
  • Ms. Romina Oxborough Ph.D.
    Sr. VP of Operations
  • Mr. Mark Austin
    Director of Technology
  • Dr. Robin Wolz
    Chief Scientific Officer
  • Ms. Hannah Esfahanian
    HR Mang.













IXI Stock - Frequently Asked Questions

How have IXI shares performed in 2023?

IXICO's stock was trading at GBX 25.50 at the start of the year. Since then, IXI stock has decreased by 23.9% and is now trading at GBX 19.40.
View the best growth stocks for 2023 here
.

How were IXICO's earnings last quarter?

IXICO plc (LON:IXI) released its earnings results on Wednesday, May, 20th. The company reported $1.01 earnings per share (EPS) for the quarter. IXICO had a trailing twelve-month return on equity of 1.18% and a net margin of 1.75%.

What other stocks do shareholders of IXICO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IXICO investors own include Motif Bio (MTFB), ReNeuron Group (RENE), Pendragon (PDG), EnQuest (ENQ) and Chariot (CHAR).

What is IXICO's stock symbol?

IXICO trades on the London Stock Exchange (LON) under the ticker symbol "IXI."

How do I buy shares of IXICO?

Shares of IXI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is IXICO's stock price today?

One share of IXI stock can currently be purchased for approximately GBX 19.40.

How much money does IXICO make?

IXICO (LON:IXI) has a market capitalization of £9.38 million and generates £7.92 million in revenue each year.

How can I contact IXICO?

IXICO's mailing address is 4th Fl, Griffin Court, 15 Long Lane, LONDON, EC1A 9PN, United Kingdom. The official website for the company is ixico.com. The company can be reached via phone at +44-20-37637499.

This page (LON:IXI) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -